PHARM.AS stock trades at €1.375 intraday as investors prepare for Pharming Group N.V.’s Q4 results due 12 March 2026; Ruconest sales and guidance will drive the move. We highlight revenue drivers, near-term guidance expectations and how upcoming data could shift the €969093340.00 market cap valuation on EURONEXT in Europe. This earnings spotlight focuses on metrics that matter for traders ahead of the report.
Earnings context and near-term catalysts
Pharming Group (PHARM.AS) reports Q4 results on 12 March 2026; investors will watch Ruconest unit volumes and any update on pipeline partnerships. The company opened today at €1.40 and the intraday range is €1.37–€1.40, showing tight pre-earnings trading. Recent MarketBeat coverage and the scheduled earnings release frame expectations for guidance changes and revenue detail source.
PHARM.AS stock: what analysts and metrics ignore
Consensus coverage is thin but valuation metrics matter: TTM price-to-sales is 3.11, price-to-book is 4.08 and reported EPS is -0.01 with a PE shown at -139.10. These figures reflect a cash-generative commercial franchise with mixed profitability. Sector peers in Healthcare trade at an average PB of 2.64, so Pharming shows a premium valuation that hinges on growth and Ruconest margins.
Q4 expectations, guidance and revenue drivers
Analyst focus will be on Ruconest U.S. pricing trends, European uptake, and partnership milestone recognition from collaborations with Novartis and Orchard. Financial growth in 2024 showed revenue growth of 16.95% year-over-year and operating cash flow growth near 89.99%, signalling cash strength to support development programs. Any upward guidance could re-rate the stock near the 50-day average of €1.47.
Technicals, trading flow and liquidity
Intraday volume stands at 4,047,188.00 versus an average volume of 14,491,020.00, giving relative volume of 0.85. RSI is 47.87 and MACD is flat near -0.03, indicating no strong trend ahead of earnings. Price sits between the 50-day (€1.47) and 200-day (€1.24) averages, which frames short-term support near €1.30 and resistance near €1.45 on the chart.
Meyka AI rates PHARM.AS with a score out of 100 and forecast
Meyka AI rates PHARM.AS with a score out of 100: 69.23 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics and analyst signals. Meyka AI’s forecast model projects a 12-month target of €2.05, a quarterly target of €1.54 and a monthly target of €1.29. Forecasts are model-based projections and not guarantees. For recent market commentary see MarketBeat news source.
Risks, opportunities and sector context
Key risks include pricing pressure in core markets, clinical setbacks for pipeline programs and a premium valuation versus the Healthcare sector average. Opportunities centre on expanding Ruconest sales, positive clinical readouts for rhC1INH programs, and milestone revenue from partnerships. In a Healthcare sector where average PE is 30.19, Pharming’s loss-making metrics and elevated PB suggest outcomes must meet or beat guidance to justify upside.
Final Thoughts
Q4 results are the immediate trigger for PHARM.AS stock. At the quoted intraday price of €1.375, the Meyka AI yearly forecast of €2.05 implies an upside of 48.73% versus current levels; shorter-term model targets are €1.54 (quarter) and €1.29 (month). Traders should watch reported Ruconest volumes, any guidance change and cash-flow commentary—Pharming’s current ratio of 3.16 supports near-term operations but valuation metrics (PB 4.08, P/S 3.11) require execution. We note Meyka AI assigns a B / HOLD grade based on balanced growth and sector comparison. Forecasts are model-based projections and not guarantees; use earnings results and management commentary to reassess risk and position sizing on EURONEXT in Europe. Meyka AI is referenced as an AI-powered market analysis platform for these model outputs.
FAQs
When does Pharming (PHARM.AS) report Q4 earnings?
Pharming Group (PHARM.AS stock) is scheduled to report Q4 results on 12 March 2026. Market reaction will hinge on Ruconest sales, guidance and partnership milestones.
What price targets does Meyka AI project for PHARM.AS stock?
Meyka AI’s model projects €1.54 for the quarter and €2.05 for 12 months, versus the current price of €1.375. Forecasts are model-based and not guarantees.
What are the main risks for PHARM.AS stock after the earnings report?
Primary risks include weaker-than-expected Ruconest sales, negative pipeline readouts and valuation compression given PB 4.08 versus the Healthcare sector. Clinical or guidance misses would likely trigger sharper downside.
How liquid is PHARM.AS stock for intraday traders?
Intraday volume today is 4,047,188.00 with a 50-day average of 14,491,020.00, giving relative volume near 0.85. Liquidity is adequate but can widen around major news.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)